• BioCurex (Richmond, British Columbia), which is developing products for cancer diagnosis, imaging and therapy, reported that its Recaf blood test for cancer is able to detect very early stages of breast cancer with a high degree of accuracy. In a blinded study vs. normal patient samples, the test showed a 90% sensitivity and 100% specificity in 42 samples of Stage I cancer. In Stage II cancer, the test showed a 93% sensitivity and 100% specificity in 45 samples. Recaf is a cancer marker found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

• Bostwick Laboratories (Richmond, Virginia), a diagnostic testing and information reference laboratory focused on urologic diseases, said the first selenium test that predicts prostate cancer risk, SeleniumHealth, is now available from the company under license from the Gerald P. Murphy Cancer Foundation. A man simply trims one or more toenails and submits the clippings for selenium content, which may predict the risk of a man's prostate cancer.

• Immucor (Norcross, Georgia), a provider of automated instrument-reagent systems to the blood transfusion industry, reported that the FDA has cleared the company's Capture-S and CMV Assays for use on the Galileo instrument. Galileo is Immucor's fully automated walk-away instrument for the hospital blood bank transfusion laboratory, donor centers and reference laboratories.

• Nanogen (San Diego), developer of advanced diagnostic products, reported that it has been issued two patents by the U.S. Patent and Trademark Office for inventions related to disease biomarkers. U.S. patent No. 7,014,854 claims use of immune system modulation to remove proteins associated with Alzheimer's disease (AD). The patent relates to a therapeutic model wherein the AD autoantibody to human glial fibrillary acidic protein can be targeted with antibodies for removal from serum. The second issued patent, No. 7,015,004, relates to the isolation and use of a biomarker to diagnose metabolic syndrome. The patent for the metabolic syndrome biomarker, an inter-alpha trypsin inhibitor, covers the steps required to isolate the protein from body fluids such as blood, serum, saliva or urine. The patent also allows the immunological detection of the biomarker.

• Vital Images (Minneapolis), a provider of enterprise-wide advanced visualization and analysis software solutions, and R2 Technology (Sunnyvale, California), a developer of computer aided detection (CAD) for earlier detection of breast cancer, actionable lung nodules and other abnormalities, reported the recent launch of the next-generation Vitrea solution, featuring the integration of R2's ImageChecker CT Lung CAD software. Vital Images' flagship product, Vitrea, creates 2D, 3D and 4D images of human anatomy from CT and MRI data. The integrated CT Lung CAD solution includes automatic detection of pulmonary nodules, AutoPoint – automatic temporal comparison of pulmonary nodules, pulmonary artery patency examination (PE) detection software and a flexible, but consolidated reporting feature scalable to the unique requirements of a clinical enterprise. The integration of the two high-performance solutions enhances the signature anticipatory automation of Vitrea's workflow, ensuring an intuitive, fast and easy-to-use solution. "The integration of two best-of-breed solutions is the vision behind the Vital Images and R2 relationship. The result is a powerful detection and analysis tool that for the first time, truly integrates R2's robust CT Lung CAD into the Vitrea workflow," said Jay Miller, Vital Images' president and CEO.